Nurix Status
The company raised $17.03 million of Series C venture funding from Celgene (NASDAQ: CELG) and other undisclosed investors on September 16, 2015, putting the company's pre-money valuation at $210 million.
Provider of drugs designed to harness the body's natural process to control protein levels. The company's drugs control protein levels and provide an opportunity for a new therapeutic approach to alter the development and progression of a broad range of diseases, enabling healthcare providers to treat proliferative and degenerative diseases.
Year Founded
2009
Employees
46
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Nurix News and Updates
Petronas CEO on energy security, energy transition, renewables
Verve Times | May 24, 2022
Exploring what gives titanium implants their remarkable biocompatibility
Verve Times | May 24, 2022
Technology assesses effectiveness and safety of drug targets
Medical Xpress | May 24, 2022
Wall Street Breakfast: The Week Ahead
Seeking Alpha | May 22, 2022
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of “Buy” by Brokerages
Defense World | May 22, 2022
Nurix's Verticals
Nurix Primary Industry Sector / Group / Code
Nurix's Trends
Nurix Metrics
SimilarWeb Unique Visitors
Headquarters
-
HQ Address Line 11700 Owens Street
-
HQ Address Line 2Suite 205
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
Nurix's Keywords
mood_badFeed is empty.
Add a review